Company: ARVN
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001655759-25-000075
Chunk: 27

Company: ARVINAS, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 27
---
;

• reviewing and reporting to our board concerning our corporate responsibility and sustainability efforts, including the impact of environmental and social issues on us; and

• overseeing an annual evaluation of our board of directors.

#### Science and Technology Committee
The members of our science and technology committee are currently Sunil Agarwal, M.D., Briggs Morrison, M.D. and Laurie Smaldone Alsup, M.D. Dr. Agarwal is the chair of our science and technology committee. The science and technology committee me t two times during the year ended December 31, 2024 , including telephonic and videoconference meetings.

Our science and technology committee’s responsibilities include:

• reviewing, evaluating, and advising our board of directors and management regarding the long-term strategic goals and objectives and the quality and direction of our research and development programs;

• monitoring and evaluating trends in research and development, and recommending to our board of directors and management emerging technologies for building the company's technological strength;

• reviewing external research and development disclosures and publications, as appropriate;

• reviewing clinical development plans, target product profiles and clinical protocol synopses for key studies, as appropriate;

• advising our board of directors and management on the scientific aspects of business development transactions;

• regularly reviewing our research and development pipeline;

• assisting our board of directors with its oversight responsibility for enterprise risk management in areas affecting our research and development; and

• reviewing our overall intellectual property strategies.

Compensation Committee Interlocks and Insider Participation

During 2024, in the period for which such person was a director, the members of our compensation committee were Everett Cunningham, Wendy Dixon, Ph.D., Laurie Smaldone Alsup, M.D. and John Young. None of our executive officers serves, or in the past has served, as a member of the board of directors or compensation committee (or other committee serving an equivalent function) of any entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. None of the members of our compensation committee is currently an officer or employee of our company.

#### Board and Committee Meetings Attendance
The full board of directors met five times during 2024. During 2024, each current member of the board of directors attended in person or participated telephonically or virtually in 75% or more of the aggregate of (i) the total number of meetings of the board of directors (held during the period for which such person has been a director) and (ii) the total number of